CHICAGO & DUBLIN--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

Fasting-acting glucagon may be needed for severe hypoglycemia. You may not be able to self-treat, so friends, family, colleagues, or caregivers may need to know how to administer glucagon. Severe low ...

The Food and Drug Administration as approved the first generic of a drug used to treat severe hypoglycemia. The agency has approved a generic glucagon for injection, 1 mg, from Amphastar ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...

Please provide your email address to receive an email when new articles are posted on . “The advent of self-administered low-dose glucagon will change the treatment of hypoglycemia significantly,” ...

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid. The FDA ...

First concentrated, ready-to-dilute liquid glucagon available for diagnostic procedures SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch ...

RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated ...

Eighteen hospitalized male diabetic patients, thirty to sixty-nine years of age, were studied. The known duration of the diabetes in the group ranged from one to twenty-five years. All patients ...

Glucagon raises the blood glucose concentration by mobilizing hepatic glycogen stores through activation of liver phosphorylase. Because crystalline glucagon is rapidly inactivated once it enters the ...

The US Food and Drug Administration (FDA) has approved the first nasally administered glucagon product (Baqsimi, Eli Lilly and Co) for the treatment of severe hypoglycemia for patients aged 4 years or ...

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an ...